CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Leflutrozole

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionDec 23, 2025
Entity authorityQ27288053 ↗
Source-derived summary

Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.

Editorial summary

The public source identifies “Leflutrozole” as chemical compound. This brief keeps that definition visible, then builds a research path around Leflutrozole, chemical and compound.

Editorial reviewUseful for establishing the present vocabulary of the subject while preserving a route back to the evidence on which that vocabulary rests. The current lead gives the account dated anchors—2017—that can be checked directly. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Leflutrozole, chemical and compound providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Leflutrozole”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Dec 23, 2025. The linked authority identifier is Q27288053. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2017.

Critical limits

A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Leflutrozole”, its source revision and the description used here.
  2. Expand the search: follow Leflutrozole primary sources, Leflutrozole archive and Leflutrozole research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Leflutrozole”?
  2. Which observation, specimen, dataset or publication supports the account?
  3. Has classification or technical consensus changed since the cited source?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Leflutrozole” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.